Expert Roundtable: Comorbidities in Atopic Dermatitis
Atopic dermatitis, especially severe atopic dermatitis, is associated with allergic, autoimmune, and cardiovascular comorbidities.
Dermatitis
DERMATITIS
FEATURE ARTICLE
LATEST NEWS
Parental History of Atopic Disease Confers Atopic Dermatitis Risk in Offspring
Maternal and paternal history of atopic disease confers an equal — and greater — risk for atopic dermatitis in offspring and increases if both parents have a history of 1 or more atopic diseases.
Atopic Dermatitis Guideline Highlights Evidence-Based Treatment Strategies
Current guidelines for the treatment of atopic dermatitis can help to inform decision-making in clinical practice.
Elevated Kallikrein 7 Expression Tied to Itch in Atopic Dermatitis
An emerging paradigm in itch biology is supported by findings that suggest KLK7 as an influence in the disease pathogenesis of atopic dermatitis.
PROMIS SD, SRI: Validated Tools for Assessing Sleep in Adults With AD
PROMIS SD and SRI 8-item bank short forms demonstrate sufficient validity and feasibility to be used as assessment tools for burden of sleep in adults with atopic dermatitis.
Maternal Depression Tied to Atopic Dermatitis in Offspring
Maternal depression in the postpartum period and beyond is associated with higher odds of atopic dermatitis for the child throughout childhood and adolescence.
Ruxolitinib Cream Shows Benefit in Atopic Dermatitis Trial
Positive topline data were announced from the pivotal phase 3 TRuE-AD2 study of ruxolitinib cream for the treatment of atopic dermatitis in patients aged ≥12 years.
Dupilumab Gets Priority Review for Atopic Dermatitis in Patients Aged 6 to 11 Years
Dupixent, an interleukin-4 receptor alpha antagonist, is currently approved for moderate to severe atopic dermatitis in patients ≥12 years old who are not adequately controlled with topical prescription therapies or when they are not advisable.
PIQ Short Forms Show Good Validity in Assessment of Itch in Adults With AD
The new Patient-Reported Outcomes Measurement Information System (PROMIS) Itch Questionnaire (PIQ) short forms may have application in clinical trial and practice.
Baricitinib Plus Topical Corticosteroids Effective in Atopic Dermatitis Study
Results showed that the 4mg dose of baricitinib plus TCS met the primary end point, with 31.5% of patients achieving EASI75 compared with 17.2% of patients in the placebo plus TCS group (P ≤.05).
Tretinoin 0.05% Lotion Safely Achieves Treatment Success in Women With Acne
Tretinoin 0.05% lotion was significantly more effective than vehicle in reducing inflammatory and noninflammatory lesions in women with moderate acne, with notable improvements in treating women with severe acne.
Want to read more?
Please login or register first to view this content.
Next post in Dermatitis
